To include your compound in the COVID-19 Resource Center, submit it here.

VEC-162: Phase III data

In a double-blind, U.S. Phase III trial in 412 patients, VEC-162 met the primary

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE